Cetuximab

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Oropharyngeal Neoplasms

Conditions

Oropharyngeal Neoplasms

Trial Timeline

Nov 1, 2005 → Nov 1, 2009

NCT ID

NCT00251381

About Cetuximab

Cetuximab is a phase 2 stage product being developed by Merck for Oropharyngeal Neoplasms. The current trial status is unknown. This product is registered under clinical trial identifier NCT00251381. Target conditions include Oropharyngeal Neoplasms.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03524820	Phase 2	Terminated	Oct 17, 2017	Dec 31, 2021	Cancer of Colon
NCT01192087	Phase 1/2	UNKNOWN	Jun 1, 2012	Jul 1, 2017	Adenoid Cystic Carcinoma
NCT01450319	Phase 2	Completed	Dec 1, 2011	Dec 1, 2014	Colorectal Neoplasms
NCT01382407	Pre-clinical	Completed	Jul 1, 2011	Apr 1, 2017	Colorectal Cancer Metastatic
NCT01230476	Phase 2	Terminated	May 1, 2010	May 1, 2015	Nasopharyngeal Carcinoma
NCT01142869	Pre-clinical	Terminated	Dec 31, 2009	Aug 5, 2014	Carcinoma, Squamous Cell
NCT01134666	Pre-clinical	Terminated	Nov 30, 2009	Aug 5, 2014	Colorectal Neoplasms
NCT01075841	Pre-clinical	Withdrawn	Mar 1, 2009	—	Neoplasms, Squamous Cell
NCT00865098	Phase 2	Completed	Mar 1, 2009	Jun 1, 2010	Carcinoma of the Head and Neck
NCT00827671	Phase 2	Terminated	Mar 1, 2009	Mar 1, 2016	Resectable Esophageal Cancer
NCT01075828	Pre-clinical	Completed	Mar 1, 2009	Jul 1, 2014	Head and Neck Cancer
NCT01074333	Pre-clinical	Terminated	Sep 1, 2008	Jan 1, 2012	Colorectal Neoplasm
NCT00714649	Phase 1/2	Completed	Jul 1, 2008	May 1, 2011	Head and Neck Cancer
NCT00522886	Phase 1	Completed	Apr 1, 2007	—	Non-small Cell Lung Cancer
NCT00251381	Phase 2	UNKNOWN	Nov 1, 2005	Nov 1, 2009	Oropharyngeal Neoplasms

Competing Products

12 competing products in Oropharyngeal Neoplasms

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Phase 1	33
Cetuximab + Cisplatin	Eli Lilly	Phase 2	52
Durvalumab + Tremelimumab	AstraZeneca	Phase 1/2	41
Cisplatin + Durvalumab + Tremelimumab	AstraZeneca	Phase 2	52
Cisplatin + Durvalumab	AstraZeneca	Phase 3	77
Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm	AstraZeneca	Phase 2	52
MEDI0457 + Durvalumab	AstraZeneca	Phase 2	52
VB10.16 + Pembrolizumab	Merck	Phase 1/2	41
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)	Merck	Phase 3	77
Paclitaxel + Carboplatin + Nivolumab	Bristol Myers Squibb	Phase 2	51
Cyclophosphamide + IRX-2 + Nivolumab	Bristol Myers Squibb	Phase 1	32
CUE-101	Cue Biopharma	Phase 2	44

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved